Lung

Viewing Page 2 of 5 | Showing Results 11 - 20 of 41

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer

1. Cohort 1(combination of niraparib and pembrolizumab): patients must have tumors with high PD-L1 expression (TPS ≥ 50%) per local assessment,...

Basir Haque, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

The Impact of a Gravity versus Vacuum Based Indwelling Tunneled Pleural Drainage System on Pain: A Multicenter, Randomized Trial

Inclusion Criteria:Clinical indications for placement of IPC for malignant pleural effusiona. Pleural effusion with symptomatic improvement in...

Christopher Gilbert
  • Swedish Medical Center

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small...

Timothy Byun, M.D.
  • St. Joseph Hospital of Orange
  • xSJH Southern California

INTR@PID Lung 037 A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor...

Ajay Kundra, M.D.
  • Providence Regional Cancer Partnership - Everett

A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)

This is a research study for participants who have been diagnosed with lung cancer and are receiving VATS (Video Assisted Thoracoscopic Surgery)...

Robert McKenna, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Protocol Number:

In male and female participants with stage IV squamous NSCLC with stable disease, partialresponse, or complete response following induction...

Raul Mena, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence Los Angeles Research Center

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

This is a Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab versus...

Rachel Sanborn, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic
  • Providence Portland Medical Center

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or...

Rachel Sanborn, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).

This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer

In male and female participants with Stage IV nonsquamous non–small-cell lung cancer(NSCLC) with stable disease (SD), partial response (PR), or...

Raul Mena, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence Los Angeles Research Center
Viewing Page 2 of 5 | Showing Results 11 - 20 of 41